Recent Media Publications

Dorothy H Bray, Director at Celtic Biotech Ltd, took the stage at CTIP to discuss the unique challenges of designing Phase I studies in oncology. Dr. Bray provided a masterclass on the strategic precision required in early-stage cancer research.

Irish biotech plans to advance crotoxin, a protein in rattlesnake venom, for the treatment of cancer following results in early-phase clinical trials. Early studies from MD Anderson and NCI confirmed therapeutic activity.

Awarded Biotech Company of the Year at the Pharma Industry Awards 2025. Celtic also made two other finalists categories. Judges: "They are a true testament of skill, passion and perseverance."

Celtic Biotech shortlisted alongside AbbVie, Amgen and Takeda for Biopharma Company of the Year.

Data from the ongoing Phase I trial of Crotoxin in patients with advanced cancer at ESMO 2025 in Berlin. Intra-patient dose escalation was safe and feasible, with a trend toward clinical benefit.

Feature on Ireland's pharma sector and the need for a home-grown pharma champion.

With strong roots in Ireland's collaborative innovation ecosystem, these medtech pioneers are building the future of medicine.

Jim and Kristen at Kentucky Reptile Zoo manage our proprietary colony of Crotalus Durissus. See how they extract the precious venom.

Celtic Biotech and 3 other EIC Accelerators were selected by the European Innovation Council to exhibit and present at the EIC stand at Dublin Tech Summit 2025.

Dr. Bray discussed Celtic Biotech's clinical drug pipeline and presented our clinical experiences with lead candidate CB-24.

CB-24 represents the world's first biologic anti-cancer monotherapy. Currently in Phase I; initial primary disease target will be non-small cell lung cancer. The drug by-passes healthy cells leaving patients with mild or no side effects.

15 of the most innovative EIC-backed companies on health and life sciences were selected for the EIC USA Soft-landing programme. Soft-landing week in San Francisco and Silicon Valley 19–24 May 2024.

Spark Crowdfunding's annual poll of early-stage businesses. Celtic Biotech featured in the Top 100.

International Business Times feature on Celtic Biotech's venom-derived cancer therapeutics.

Celtic Biotech: Pioneering Breakthrough remedies for Terminal Health Conditions.

Celtic Biotech selected in EIT Health Catapult Top 30 life science companies.

Meet the startup developing novel cancer therapies from snake venom crotoxin.

Six high-potential start-ups have been selected as semi-finalists in the EIT Health Catapult 2023-24 competition. They will join 24 other European companies for mentorship and training.

Brothers Paul and John Reid have assembled an international team of experts in biotech, pharma and business to help save the lives of lung cancer patients.

In further recognition of its potential, Celtic Biotech reached the semi-finals of the prestigious EIT Catapult accelerator programme.

Enterprise Ireland announcement of EIC Accelerator funding for Celtic Biotech and three other client companies.

Business Plus | Ireland: Four Irish medical start-ups granted €18m in EU funding.